Адаптована клінічна настанова, заснована на доказах грип та гострі респіраторні інфекції Склад мультидисциплінарної робочої групи з опрацювання клінічної настанови


ПОСИЛАННЯ [WHO Guidelines for Pharmacological Management of Pandemic Influenza A (H1N1) 2009 and other Influenza Viruses (February 2010)]



жүктеу/скачать 1.27 Mb.
бет18/18
Дата24.06.2016
өлшемі1.27 Mb.
#156575
1   ...   10   11   12   13   14   15   16   17   18

ПОСИЛАННЯ [WHO Guidelines for Pharmacological Management of Pandemic Influenza A (H1N1) 2009 and other Influenza Viruses (February 2010)]


  1. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, de Jong MD, et al.Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008;358(3):261-73.

  2. Alves Galvao MG, Rocha Crispino Santos MA, Alves da Cunha AJ. Amantadine and rimantadine for influenza A in children and the elderly. Cochrane Database Syst Rev 2008(1):CD002745.

  3. Barr CE, Schulman K, Iacuzio D, Bradley JS. Effect of oseltamivir on the risk of pneumonia and use of health care services in children with clinically diagnosed influenza. Curr Med Res Opin 2007;23(3):523-31.

  4. Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB. Reye’s syndrome in the United States from 1981 through 1997. N Engl J Med 1999;340(18):1377-82.

  5. Beliaev AL, Burtseva EI, Slepushkin AN, Beliaeva NA, Nosik NN, Lavrukhina LA, et al. [Arbidole–a new drug for prevention of influenza and acute viral respiratory infections in children]. Vestn Ross Akad Med Nauk 1996(8):34-7.

  6. Bell M, Hunter JM, Mostafa SM. Nebulised ribavirin for influenza B viral pneumonia in a ventilated immunocompromised adult. Lancet 1988;2(8619):1084-5.

  7. Bernard GR, Luce JM, Sprung CL, Rinaldo JE, Tate RM, Sibbald WJ, et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 1987;317(25):1565-70.

  8. Bernstein DI, Reuman PD, Sherwood JR, Young EC, Schiff GM. Ribavirin small-particleaerosol treatment of influenza B virus infection. Antimicrob Agents Chemother 1988;32(5):761-4.

  9. Birnkrant D, Cox E. The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 2009;361(23):2204-7.

  10. Blumentals WA, Song X. The safety of oseltamivir in patients with influenza: analysis of healthcare claims data from six influenza seasons. MedGenMed 2007;9(4):23.

  11. Boriskin YS, Leneva IA, Pecheur EI, Polyak SJ. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem 2008;15(10):997-1005.

  12. Bowles SK, Lee W, Simor AE, Vearncombe M, Loeb M, Tamblyn S, et al. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000. J Am Geriatr Soc 2002;50(4):608-16.

  13. Burch J, Paulden M, Conti S, Stock C, Corbett M, Welton NJ, et al. Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation. Health Technol Assess 2009;13(58):1-265, iii-iv.

  14. Burch J, Conti for the CRD/CHE Technology Assessment Group (Centre for Reviews and Dissemination/Centre for Health Economics), University of York. Influenza – zanamivir, amantadine and oseltamivir (review): assessment report. http://www.nice.org.uk/Guidance/TA168, 2008.

  15. Cao B, Li XW, Mao Y, Wang J, Lu HZ, Chen YS, et al. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med 2009;361(26):2507-17.

  16. Carter MJ. A rationale for using steroids in the treatment of severe cases of H5N1 avian influenza. J Med Microbiol 2007;56(Pt 7):875-83.

  17. Casscells SW, Granger E, Kress AM, Linton A, Madjid M, Cottrell L. Use of oseltamivir after influenza infection is associated with reduced incidence of recurrent adverse cardiovascular outcomes among military health system beneficiaries with prior cardiovascular diseases. Circ Cardiovasc Qual Outcomes 2009;2(2):108-15.

  18. CDC, Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep 2009;58(16):433-5.

  19. CDC, Reye syndrome – Ohio, Michigan. MMWR Morb Mortal Wkly Rep 1980;29.

  20. Chan-Tack KM, Murray JS, Birnkrant DB. Use of ribavirin to treat influenza. N Engl J Med 2009;361(17):1713-4.

  21. Cole JA, Loughlin JE, Ajene AN, Rosenberg DM, Cook SE, Walker AM. The effect of zanamivir treatment on influenza complications: a retrospective cohort study. Clin Ther 2002;24(11):1824-39.

  22. Denholm JT, Gordon CL, Johnson PD, Hewagama SS, Stuart RL, Aboltins C, et al. Hospitalised adult patients with pandemic (H1N1) 2009 influenza in Melbourne, Australia. Med J Aust 2010;192(2):84-6.

  23. de Serres, G., Shedding of novel 2009 pandemic H1N1 (nH1N1)v Virus at one week post illness onset, Abstract K-1918a. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2009 12th – 15th Sept; San Francisco, CA.

  24. Dominguez-Cherit G, Lapinsky SE, Macias AE, Pinto R, Espinosa‐Perez L, de la Torre A, et al. Critically Ill patients with 2009 influenza A(H1N1) in Mexico. JAMA 2009;302(17):1880-7.

  25. Drinevskii VP, Osidak LV, Natsina VK, Afanas’eva OI, Mil’kint KK, Danini GV, et al. [Chemotherapeutics for treatment of influenza and other viral respiratory tract infections in children]. Antibiot Khimioter 1998;43(9):29-34.

  26. Dutkowski R, et al. High-Dose Oseltamivir Regimens Are Well Tolerated by Healthy Adults. Abstract V-1062. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2009 12th – 15th Sept; San Francisco, CA.

  27. Echevarria-Zuno S, Mejia-Arangure JM, Mar-Obeso AJ, Grajales-Muniz C, Robles-Perez E, Gonzalez-Leon M, et al. Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis. Lancet 2009. [epub in print].

  28. Electronic Medicines Compendium, Copegus 200mg Film-coated Tablets – Summary of Product Characteristics (SPC) – electronic Medicines Compendium (eMC). Accessed 6th Nov 2009 at http://emc.medicines.org.uk/document.aspx?documentId=11755.

  29. Englund J, Zerr D, Heath J, et al. Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients – Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep 2009;58(32):893-6.

  30. Freemantle N, Calvert M. What can we learn from observational studies of oseltamivir to treat influenza in healthy adults? BMJ 2009;339:b5248.

  31. French DD, Margo CE. Postmarketing surveillance of corneal edema, Fuchs dystrophy, and amantadine use in the Veterans Health Administration. Cornea 2007;26(9):1087-9.

  32. Gagarinova VM, Ignat’eva GS, Sinitskaia LV, Ivanova AM, Rodina MA, Tur’eva AV. [The new chemical preparation arbidol: its prophylactic efficacy during influenza epidemics]. Zh Mikrobiol Epidemiol Immunobiol 1993(5):40-3.

  33. Gooskens J, Jonges M, Claas EC, Meijer A, van den Broek PJ, Kroes AM. Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus. JAMA 2009;301(10):1042-6.

  34. Gums JG, Pelletier EM, Blumentals WA. Oseltamivir and influenza-related complications, hospitalization and healthcare expenditure in healthy adults and children. Expert Opin Pharmacother 2008;9(2):151-61.

  35. Guskova TA, Leneva IA, Fedyakina IT, Chistyakov VV, Glushkov RG, Chem. Pharm. J. (Russian), 1999, 6, 14.

  36. Halpin TJ, Holtzhauer FJ, Campbell RJ, Hall LJ, Correa-Villasenor A, Lanese R, et al. Reye’s syndrome and medication use. JAMA 1982;248(6):687-91.

  37. Hanshaoworakul W, Simmerman JM, Narueponjirakul U, Sanasuttipun W, Shinde V, Kaewchana S, et al. Severe human influenza infections in Thailand: oseltamivir treatment and risk factors for fatal outcome. PLoS One 2009;4(6):e6051.

  38. Hayden FG, Sable CA, Connor JD, Lane J. Intravenous ribavirin by constant infusion for serious influenza and parainfluenzavirus infection. Antivir Ther 1996;1(1):51-6.

  39. Hayden FG. Prevention and treatment of influenza in immunocompromised patients. Am J Med 1997;102(3A):55-60; discussion 75-6.

  40. Hedrick JA, Barzilai A, Behre U, Henderson FW, Hammond J, Reilly L, et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 2000;19(5):410-7.

  41. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April – June 2009. N Engl J Med 2009;361(20):1935-44.

  42. Jamieson DJ, Honein MA, Rasmussen SA, Williams JL, Swerdlow DL, Biggerstaff MS, et al. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet 2009;374(9688):451-8.

  43. Jefferson T, Demicheli V, Di Pietrantonj C, Rivetti D. Amantadine and rimantadine for influenza A in adults. Cochrane Database Syst Rev 2006(2):CD001169.

  44. Jefferson T, Jones M, Doshi P, Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ 2009;339:b5106.

  45. Kaiser L, Keene ON, Hammond JM, Elliott M, Hayden FG. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch Intern Med 2000;160(21):3234-40.

  46. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza‐related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003;163(14):1667-72.

  47. Kawai N, Ikematsu H, Iwaki N, Maeda T, Kawashima T, Hirotsu N, et al. Comparison of the effectiveness of Zanamivir and Oseltamivir against influenza A/H1N1, A/H3N2, and B. Clin Infect Dis 2009;48(7):996-97.

  48. Kawai N, Ikematsu H, Hirotsu N, Maeda T, Kawashima T, Tanaka O, et al. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007 – 2008 and 2008 – 2009 influenza seasons. Clin Infect Dis 2009;49(12):1828-35.

  49. Keyser LA, Karl M, Nafziger AN, Bertino JS, Jr. Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. Arch Intern Med 2000;160(10):1485-8.

  50. Khazeni N, Hutton DW, Garber AM, Hupert N, Owens DK. Effectiveness and costeffectiveness of vaccination against pandemic influenza (H1N1) 2009. Ann Intern Med 2009;151(12):829-39.

  51. Kidd IM, Down J, Nastouli E, Shulman R, Grant PR, Howell DC, et al. H1N1 pneumonitis treated with intravenous zanamivir. Lancet 2009;374(9694):1036.

  52. Kimberlin DW, Shalabi M, Abzug MJ, Lang D, Jacobs RF, Storch G, et al. Safety of Oseltamivir Compared With the Adamantanes in Children Less Than 12 Months of Age. Pediatr Infect Dis J 2009. [epub ahead of print].

  53. Kitching A, Roche A, Balasegaram S, Heathcock R, Maguire H. Oseltamivir adherence and side effects among children in three London schools affected by influenza A(H1N1)v, May 2009 – an internet-based cross-sectional survey. Euro Surveill 2009;14(30):19287.

  54. Knight V, McClung HW, Wilson SZ, Waters BK, Quarles JM, Cameron RW, et al. Ribavirin Small-particle aerosol treatment of influenza. Lancet 1981;2(8253):945-9.

  55. Kolobukhina LV, Merkulova LN, Shchelkanov M, Burtseva EI, Isaeva EI, Malyshev NA, et al. [Efficacy of ingavirin in adults with influenza]. Ter Arkh 2009;81(3):51-4.

  56. Kramarev SA, Palatnaya LA, Litus VI, Rus. Med. J. (Russian), 2003, 21, 1050.

  57. Kubar, OI, Stepanova, LA, Safonova, LS, Rosaeva, NR, IVth Russian National Congress “Man and Medicine”, Moscow, 1997, p. 269.

  58. Lee N, Chan PK, Hui DS, Rainer TH, Wong E, Choi KW, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009;200(4):492-500.

  59. Lee N, Chan PK, Choi KW, Lui G, Wong B, Cockram CS, et al. Factors associated with early hospital discharge of adult influenza patients. Antivir Ther 2007;12(4):501-8.

  60. Li IW, Hung IF, To KK, Chan KH, Wong SS, Chan JF, et al. The natural viral load profile of patients with pandemic swine-origin influenza A H1N1 2009 (pH1N1) and the effect of oseltamivir treatment. Chest 2010 [epub ahead of print].

  61. Libster R, Bugna J, Coviello S, Hijano DR, Dunaiewsky M, Reynoso N, et al. Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina. N Engl J Med 2010;362(1):45-55.

  62. Liem NT, Tung CV, Hien ND, Hien TT, Chau NQ, Long HT, et al. Clinical features of human influenza A (H5N1) infection in Vietnam: 2004-2006. Clin Infect Dis 2009;48(12):1639-46.

  63. Louie JK, Acosta M, Jamieson DJ, Honein MA. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med 2010;362(1):27-35.

  64. Louie JK, Acosta M, Winter K, Jean C, Gavali S, Schechter R, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 2009;302(17):1896-902.

  65. Lye, D., Oseltamivir therapy and viral shedding in pandemic (H1N1) 2009. Abstract V-1269c. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2009 12th – 15th Sept; San Francisco, CA.

  66. Madjid M, Curkendall S, Blumentals WA. The influence of oseltamivir treatment on the risk of stroke after influenza infection. Cardiology 2009;113(2):98-107.

  67. MEDA. Position paper: Ribavirin for treatment of influenza. Virazole 12. June 2009.

  68. McGeer A, Green KA, Plevneshi A, Shigayeva A, Siddiqi N, Raboud J, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007;45(12):1568-75.

  69. Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004;39(9):1300-6.

  70. Nordstrom BL, Oh K, Sacks ST, LʹItalien GJ. Skin reactions in patients with influenza treated with oseltamivir: a retrospective cohort study. Antivir Ther 2004;9(2):187-95.

  71. Nordstrom BL, Sung I, Suter P, Szneke P. Risk of pneumonia and other complications of influenza‐like illness in patients treated with oseltamivir. Curr Med Res Opin 2005;21(5):761-8.

  72. Orzeck EA, Shi N, Blumentals WA. Oseltamivir and the risk of influenza-related complications and hospitalizations in patients with diabetes. Clin Ther 2007;29(10):2246-55.

  73. Osterlund P, Pirhonen J, Ikonen N, Ronkko E, Strengell M, Makela SM, et al. Pandemic H1N1 2009 influenza A virus induces weak cytokine responses in human macrophages and dendritic cells and is highly sensitive to the antiviral actions of interferons. J Virol 2010;84(3):1414-22.

  74. Peters PH, Moscona A, Schulman KL, Barr CE. Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000 – 2005. Medscape J Med 2008;10(6):131.

  75. Piedra PA, Schulman KL, Blumentals WA. Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. Pediatrics 2009;124(1):170-8.

  76. Quispe-Laime AM, Bracco JD, Barberio PA, Campagne CG, Rolfo VE, Umberger R, et al. H1N1 influenza A virus‐associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment. Intensive Care Med 2010;36(1):33-41.

  77. Rello J, Rodriguez A, Ibanez P, Socias L, Cebrian J, Marques A, et al. Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain. Crit Care 2009;13(5):R148.

  78. Riner A, Chan-Tack KM, Murray JS. Original research: Intravenous ribavirin – review of the FDA’s Emergency Investigational New Drug Database (1997-2008) and literature review. Postgrad Med 2009;121(3):139-46.

  79. Rodriguez WJ, Hall CB, Welliver R, Simoes EA, Ryan ME, Stutman H, et al. Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo‐controlled trial. J Pediatr 1994;125(1):129-35.

  80. Sessler CN, Gray ND. Intensive care management of life‐threatening avian influenza A (H5N1). Respirology 2008;13 Suppl 1:S27-32.

  81. Shun-Shin M, Thompson M, Heneghan C, Perera R, Harnden A, Mant D. Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials. BMJ 2009;339:b3172.

  82. Shuster AM, Shumilov VI, Shevtsov VA, Mar’in GG, Kozlov VN. [Arbidol used in the prophylaxis of acute respiratory viral infections and their complications in servicemen]. Voen Med Zh 2004;325(9):44-5, 80.

  83. Slopen ME, Mosquera MC, Balter S, Kerker BD, Marx MA, Pfeiffer MR, et al. Patients hospitalized with 2009 pandemic influenza A (H1N1) – New York City, May 2009. MMWR Morb Mortal Wkly Rep 2010;58(51):1436-40.

  84. Smith CB, Charette RP, Fox JP, Cooney MK, Hall CE. Lack of effect of oral ribavirin in naturally occurring influenza A virus (H1N1) infection. J Infect Dis 1980;141(5):548-54.

  85. Starko KM, Ray CG, Dominguez LB, Stromberg WL, Woodall DF. Reye’s syndrome and salicylate use. Pediatrics 1980;66(6):859-64.

  86. Steel J, Staeheli P, Mubareka S, Garcia-Sastre A, Palese P, Lowen AC. Transmission of pandemic H1N1 influenza virus and impact of prior exposure to seasonal strains or interferon treatment. J Virol 2010;84(1):21-6.

  87. Stein DS, Creticos CM, Jackson GG, Bernstein JM, Hayden FG, Schiff GM, et al. Oral ribavirin treatment of influenza A and B. Antimicrob Agents Chemother 1987;31(8):1285-7.

  88. Steinberg KP, Hudson LD, Goodman RB, Hough CL, Lanken PN, Hyzy R, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006;354(16):1671-84.

  89. Sugaya N, Mitamura K, Yamazaki M, Tamura D, Ichikawa M, Kimura K, et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 2007;44(2):197-202.

  90. Tanaka T, Nakajima K, Murashima A, Garcia‐Bournissen F, Koren G, Ito S. Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women. CMAJ 2009;181(1-2):55-8.

  91. Tang BM, Craig JC, Eslick GD, Seppelt I, McLean AS. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and metaanalysis. Crit Care Med 2009;37(5):1594-603.

  92. Tappenden P, Jackson R, Cooper K, Rees A, Simpson E, Read R, et al. Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation. Health Technol Assess 2009;13(11):iii, ix-xii, 1-246.

  93. Uchaikin VF, Kharlamova SG, Cheshik SG, Pediatrics (Russian), 2004, 5, 73.

  94. van der Vries E, van den Berg B, Schutten M. Fatal oseltamivir-resistant influenza virus infection. N Engl J Med 2008;359(10):1074-6.

  95. Waldman RJ, Hall WN, McGee H, Van Amburg G. Aspirin as a risk factor in Reye’s syndrome. JAMA 1982;247(22):3089-94.

  96. Wallensten A, Oliver I, Lewis D, Harrison S. Compliance and side effects of prophylactic oseltamivir treatment in a school in South West England. Euro Surveill 2009;14(30):19285.

  97. Wentges-van Holthe N, van Eijkeren M, van der Laan JW. Oseltamivir and breastfeeding. Int J Infect Dis 2008;12(4):451.

  98. WHO Guidelines for Pharmacological Management of Pandemic (H1N1) 2009 Influenza and other Influenza Viruses. 20 August 2009 ed. Geneva: WHO, 2009.

  99. WHO, Oseltamivir-resistant pandemic (H1N1) 2009 influenza virus, October 2009. Wkly Epidemiol Rec 2009;84(44):453-9.

  100. Witkop CT, Duffy MR, Macias EA, Gibbons TF, Escobar JD, Burwell KN, et al. Novel Influenza A (H1N1) Outbreak at the U.S. Air Force Academy Epidemiology and Viral Shedding Duration. Am J Prev Med 2009;[Epub ahead of print].

  101. Woo PC, Tung ET, Chan KH, Lau CC, Lau SK, Yuen KY. Cytokine profiles induced by the novel swine‐origin influenza A/H1N1 virus: implications for treatment strategies. J Infect Dis 2010;201(3):346-53.

  102. Yi Z, Ke X, Yuan X, Bao X, Medline PMID: 15266832 (Chinese), 2004, 26, 289.

  103. Zarychanski R, Stuart TL, Kumar A, Doucette S, Elliott L, Kettner J, et al. Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection. CMAJ 2010;182(3):257-64.

Література, використана в процесі адаптації клінічної настанови


  1. Seasonal Influenza in Adults and Children – Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management: Clinical Practice Guidelines of the Infectious Diseases Society of America (2009).

  2. NICE clinical guideline 69 «Respiratory tract infections – antibiotic prescribing», 2008.

  3. WHO Guidelines for Pharmacological Management of Pandemic Influenza A (H1N1) 2009 and other Influenza Viruses (February 2010).

  4. ВООЗ Клінічні методи ведення хворих, які інфіковані новим вірусом грипу A(H1N1): попередня настанова 21 травня 2009 року.

  5. А.М. Печінка, М.І. Дземан. Гострі респіраторні захворювання: питання клінічної діагностики та лікування// Укр. мед. часопис. – № 5(79), 2010. – с.94-103.

6. WHO Regional office for Europe «Сезонний грип: ключові аспекти клінічного ведення тяжких форм хвороби (2011)» (http://www.euro.who.int/__data/assets/pdf_file/0007/­154888/flu_case_­management_rus.pdf

1 Оскільки дослідження та лікарі використовують трохи різні терміни для РІ, термінологія, використовувана в цій настанові для РІ, охоплює цілий ряд гострих симптомів, а також потенційний діагноз, якщо необхідно. Наприклад:

  • Гострий середній отит (ГСО) є діагнозом, який заснований на симптомах і дослідженні барабанної перетинки. Двома загальними симптомами гострого середнього отиту є вушний біль (гострий біль у вусі) і оторея.

  • Гострий кашель/гострий бронхіт – гострий кашель є основним симптомом гострого бронхіту. Діагноз гострого болю в горлі відповідає вірусному/бактеріальному фарингіту та тонзиліту.

  • Гострий риносинусит також називають гострим синуситом в деякій медичній літературі.

2 Для більш детального визначення терміну «кількість пацієнтів, які потребують лікування» (КППЛ), зверніться до словника

Коментар робочої групи: Кількість пацієнтів, які потребують лікування (КППЛ) термін, що використовується при оцінці ефективності медичних втручаннь, як правило, для лікування за допомогою лікарських засобів. КППЛ – среднє число пацієнтів, яких потрібно лікувати для попередження одного додаткового небажаного наслідку (тобто кількість пацієнтів, котрі повинні зазнати медичного втручання, щоб був досягнутий один позитивний ефект порівняно з контрольною групою в клінічних випробуваннях). Ця величина, обратна зниженню абсолютного ризику. КППЛ була описана в 1988 році. Чим вище КППЛ, тим менш ефективне лікування.

3 Цей огляд перестав проводитись у бібліотеці Кокрейн після 3 випуску, 2007 року. Автори більше не бачили необхідності працювати у напрямку оновлення огляду, у зв’язку з іншими робочими потребами.

4 Критерії Сентора: наявність ексудату у мигдалинах, болючі передньошийні лімфатичні вузли, лімфоаденопатія або лімфаденіт, гарячка в анамнезі і відсутність кашлю.

5 Переведені для зручності з доларів США 2001 року у фунти стерлінги 2006/7 з використанням курсу паритету купівельної спроможності 0,626 (www.oecd.org/STD/PPP) і скориговані на інфляцію у розмірі 22% (www.pssru.ac.uk/pdf/uc/uc2006/uc2006.pdf).

6 гострого риносинуситу також може бути переданий в якості гострого синуситу в деякій медичній літературі.

2014

жүктеу/скачать 1.27 Mb.

Достарыңызбен бөлісу:
1   ...   10   11   12   13   14   15   16   17   18



©dereksiz.org 2024
әкімшілігінің қараңыз
    Басты бет